In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Abbott buys Hokuriku for $292mm

Executive Summary

Abbott will pay $292mm (Y38bn) to acquire the 33.3% of Hokuriku Seyaku it does not already own. Abbott acquired 66.7% of the company when it bought out BASF's pharmaceutical divisions, including Hokuriku's parent, Knoll.
Deal Industry
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Partial Acquisition
    • Payment Includes Cash

Related Companies